Citigroup Reiterates Buy Rating for GSK (LON:GSK)

GSK (LON:GSK)‘s stock had its “buy” rating reissued by stock analysts at Citigroup in a report released on Tuesday, MarketBeat.com reports. They currently have a GBX 1,900 price target on the stock. Citigroup’s target price points to a potential upside of 4.54% from the stock’s current price.

Several other research firms have also commented on GSK. Shore Capital reaffirmed a “buy” rating on shares of GSK in a report on Thursday, January 8th. Jefferies Financial Group restated a “buy” rating and set a GBX 2,100 price objective on shares of GSK in a research note on Wednesday, January 7th. UBS Group reaffirmed a “neutral” rating and issued a GBX 1,940 target price on shares of GSK in a research report on Friday, January 23rd. JPMorgan Chase & Co. reissued an “underweight” rating on shares of GSK in a report on Wednesday, January 7th. Finally, Berenberg Bank increased their price objective on shares of GSK from GBX 1,600 to GBX 1,660 and gave the stock a “hold” rating in a report on Monday, November 24th. Three analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of GBX 1,839.29.

GSK Stock Down 2.4%

Shares of LON:GSK opened at GBX 1,817.50 on Tuesday. The company’s fifty day moving average is GBX 1,820.36 and its two-hundred day moving average is GBX 1,640.14. The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81. GSK has a 1-year low of GBX 1,242.50 and a 1-year high of GBX 1,909.73. The stock has a market capitalization of £73.32 billion, a price-to-earnings ratio of 13.67, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31.

GSK (LON:GSK) last announced its quarterly earnings data on Wednesday, October 29th. The company reported GBX 55 earnings per share for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. Equities analysts anticipate that GSK will post 175.980975 EPS for the current year.

Insider Activity

In related news, insider Wendy Becker purchased 441 shares of the company’s stock in a transaction on Friday, December 19th. The shares were bought at an average cost of GBX 1,809 per share, for a total transaction of £7,977.69. Also, insider Jonathan Symonds purchased 1,650 shares of GSK stock in a transaction dated Monday, December 22nd. The stock was bought at an average cost of GBX 1,810 per share, with a total value of £29,865. Corporate insiders own 0.20% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.